Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Artificial intelligence and machine learning applications in iron deficiency anemia: A systematic review (2015‑2025)

Ronak Patel, Imad Karam, Alaukika Agarwal et al. Nov 03, 2025 pp. 6470-6470 10.1182/blood-2025-6470

Abstract Background: Iron deficiency anemia (IDA) affects approximately 1.2 billion people worldwide, yet ferritin-based diagnosis is confou...

Targeting inflammation in sickle cell disease: Association of GLP-1 agonist use with improved survival and reduced sickle cell crisis and cardiopulmonary complications

Asfand Yar Cheema, Mishaal Munir, Aashray Mandala et al. Nov 03, 2025 pp. 2970-2970 10.1182/blood-2025-2970

Abstract Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by chronic hemolysis, vaso-occlusion, and a systemic infla...

Impact of obesity on response to first line treatment in primary immune thrombocytopenia - data from Latin America population

Joao Conrado dos-Santos, Marina Pinto, Julia Tavares et al. Nov 03, 2025 pp. 3045-3045 10.1182/blood-2025-3045

Abstract Introduction Although Immune thrombocytopenia (ITP) natural history and treatment have been well characterized,...

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Noemie Leblay, Sungwoo Ahn, Alexandra Poos et al. Nov 03, 2025 pp. 2163-2163 10.1182/blood-2025-2163

Abstract Despite recent advances in multiple myeloma (MM) treatment, a subset of patients continues to experience early disease progression...

Optimal dose and duration of venetoclax for induction therapy in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis

Mamoon Ahmed, Farooq Ashraf, Anas Al-sadi et al. Nov 03, 2025 pp. 2831-2831 10.1182/blood-2025-2831

Abstract Background Venetoclax, a selective BCL-2 inhibitor, has become a key component of induction therapy for newly d...

Tailoring pediatric to adult care transition from high to low-resource settings: A user-centered design approach

Tarun Aurora, Danila Sala, Clarisse Lobo et al. Nov 03, 2025 pp. 2589-2589 10.1182/blood-2025-2589

Abstract Background Brazil is home to one of the largest populations of individuals with sickle cell disease (SCD) in the world, with an est...

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

William Pilcher, Marina Michaud, Sarthak Satpathy et al. Nov 03, 2025 pp. 2179-2179 10.1182/blood-2025-2179

Abstract Introduction: Multiple Myeloma (MM) is a complex hematologic malignancy, where patients often display one or more potentially high...

Cervical cancer screening outcomes in adolescents and young adults with sickle cell disease age 21–29: A retrospective chart review

Ayesha Farooqui, Naomi Oravitz, Marwah Farooqui Nov 03, 2025 pp. 7886-7886 10.1182/blood-2025-7886

Abstract Background: Cervical cancer screening is essential for early detection and prevention, particularly among adole...

Blood heavy-metal levels and risk of hematologic cancer in u.S. adults: Nhanes 2021–2023

Kirti Arora, Preksha Singh, Laurie Matt-Amaral Nov 03, 2025 pp. 6841-6841 10.1182/blood-2025-6841

Abstract Blood Heavy-Metal Levels and Risk of Hematologic Cancer in U.S. Adults: NHANES 2021–2023 Background: Heavy meta...

MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial

Surita Dalal, Jane Shingles, Sean Girvan et al. Nov 03, 2025 pp. 679-679 10.1182/blood-2025-679

Abstract Introduction: We have previously reported improved survival in patients (pts) with recurrent gene mutations following treatment wit...

Very low risk for secondary malignancies with btkis in Waldenström macroglobulinemia: A retrospective real-world multicenter study.

Francesco Autore, Annamaria Frustaci, Veronica Peri et al. Nov 03, 2025 pp. 5390-5390 10.1182/blood-2025-5390

Abstract The prolonged survival of patients with Waldenström Macroglobulinemia (WM), together with the increasing use of chemoimmunotherapy...

Rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for R/R Acute Myeloid Leukemia

Jacob Herstein, Fadi Haddad, Kelly Chien et al. Nov 03, 2025 pp. 6981-6981 10.1182/blood-2025-6981

Abstract Mutations in isocitrate dehydrogenase (IDH1, IDH2) are present in ~20% of adult patients with acute myeloid leukemia (AML) (Im, 201...

The ribosome biogenesis inhibitor CX-5461 increases platelet count in humans and enhances murine megakaryopoiesis

Vijay Bhoopalan, Amandeep Kaur, James Hearn et al. Nov 03, 2025 pp. 3013-3013 10.1182/blood-2025-3013

Abstract Treatment of sub-optimal platelet production and thrombocytopenia remains a major clinical challenge and thrombocytopenia is a comm...

Impact of renal impairment and lymphodepletion regimen on outcomes after CAR T-cell therapy in relapsed/refractory multiple myeloma

Nora Grieb, Thomas Wiemers, Patrick Born et al. Nov 03, 2025 pp. 5853-5853 10.1182/blood-2025-5853

Abstract Introduction Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized treatment for relapsed/refractory multiple myeloma (...

TIM3-Galectin9 axis drives CSF-1R–independent senescent macrophage and TSCM crosstalk in chronic graft-versus-host disease

Xiaodong Xie, Yuxi Xu, Fengjuan Tian et al. Nov 03, 2025 pp. 4085-4085 10.1182/blood-2025-4085

Abstract Background: Chronic graft-versus-host disease (cGVHD) remains a major cause of morbidity post-allogeneic hematopoietic cell transpla...

Prevalence of iron deficiency in pregnant women with inherited bleeding disorders: A retrospective analysis

Gretchen York, Sydney Taylor, Ming Lim Nov 03, 2025 pp. 6236-6236 10.1182/blood-2025-6236

Abstract Introduction: Women with an inherited bleeding disorder (IBD) are at an increased risk of developing iron deficiency with or withou...

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

John M. Burke, Nancy Bartlett, Gary L. Simmons et al. Nov 03, 2025 pp. 3730-3730 10.1182/blood-2025-3730

Abstract Background and Significance: R-CHOP as first-line (1L) therapy for LBCL has a cure rate of ~60%. However, ~10% of patients (pts) hav...

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Luca Laurenti, Antonio Mosca, Feliciana Guglielmi et al. Nov 03, 2025 pp. 7427-7427 10.1182/blood-2025-7427

Abstract BACKGROUND Covalent Bruton's tyrosine kinase inhibitors (cBTKi) have revolutionized the treatment of Chronic Lymphocytic Leukemia (...

Finding ferritin footprints in 5-fluorouracil-induced cardiotoxicity

Grace Ferri, John Hensien, Alexander Stanisic et al. Nov 03, 2025 pp. 2907-2907 10.1182/blood-2025-2907

Abstract Introduction Fluoropyrimidines including 5-fluorouracil (5-FU) are used in the treatment of patients with gastrointestinal malignan...

The bispecific blind spot: Uncovering real-world inequities in diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma therapy access

Gene Ho, Olive Mbah, Cleo Ryals et al. Nov 03, 2025 pp. 8068-8068 10.1182/blood-2025-8068

Abstract Introduction: Bispecific antibodies (BsAbs) and CAR T-cell therapy (CAR T) represent significant advancements in hematologic malign...

IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma

Hatice Satilmis, Adrien Denis, Emma Verheye et al. Nov 03, 2025 pp. 5696-5696 10.1182/blood-2025-5696

Abstract Introduction Immunotherapy has shown clinical promise in multiple myeloma (MM), but relapse remains common, largely due to the immu...

CELF2-deficient mutations promote B-cell lymphoma development by inducing a germinal center B-cell fate

Tao Pan, Yuqin Song, Xiaomin Wang Nov 03, 2025 pp. 5038-5038 10.1182/blood-2025-5038

Abstract RNA-binding proteins (RBPs) are key regulators in the processes of RNA transcription and translation. As an important member of RBP...

Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors

Sarah Peterson, Megan Othus, Katie Russell et al. Nov 03, 2025 pp. 5265-5265 10.1182/blood-2025-5265

Abstract Introduction: Mutations in TP53 are recurrent in myeloid neoplasms and are often associated with complex cytogenetics, therapy-rela...

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Yumeng Zhang, Daniel DeAvila, Fatima Tuz Zahra et al. Nov 03, 2025 pp. 8017-8017 10.1182/blood-2025-8017

Abstract Background: Cytokine-release syndrome (CRS) and immune-effector-cell–associated neurotoxicity syndrome (ICANS) remain the principal...

A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia

Annalisa Condorelli, Chiara Pavoni, Federico Lussana et al. Nov 03, 2025 pp. 3513-3513 10.1182/blood-2025-3513

Abstract Background . Measurable residual disease (MRD) in Acute Myeloid Leukemia (AML) is a prognostic indicator used in clinical practice f...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page